Develops oral small‑molecule therapeutics for immune‑mediated inflammatory diseases (e.g., atopic dermatitis, chronic urticaria) to control inflammation, prevent tissue damage and achieve long‑term remission. AI/ML-driven discovery focusing on highly selective chymase inhibitors that target mast‑cell–mediated inflammation, epithelial barrier damage and fibrosis.